{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:04:14Z","timestamp":1789574654413,"version":"build-2803163510"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,9,14]],"date-time":"2016-09-14T00:00:00Z","timestamp":1473811200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Merck Pharmaceutical Corporation"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Papillomavirus Research"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.pvr.2017.04.004","type":"journal-article","created":{"date-parts":[[2017,4,23]],"date-time":"2017-04-23T02:31:58Z","timestamp":1492914718000},"page":"142-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":160,"special_numbering":"C","title":["The feminization of HPV: How science, politics, economics and gender norms shaped U.S. HPV vaccine implementation"],"prefix":"10.1016","volume":"3","author":[{"given":"Ellen M.","family":"Daley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl A.","family":"Vamos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika L.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory D.","family":"Zimet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeev","family":"Rosberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Merrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nolan S.","family":"Kline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.pvr.2017.04.004_bib1","first-page":"814","article-title":"Ten great public health achievements\u2014United States, 2001\u20132010","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"6","key":"10.1016\/j.pvr.2017.04.004_bib2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2105\/AJPH.2016.303122","article-title":"The feminization of HPV: reversing gender biases in US human papillomavirus vaccine policy","volume":"106","author":"Daley","year":"2016","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.pvr.2017.04.004_bib3","series-title":"The Feminization of American Culture","author":"Douglas","year":"1977"},{"key":"10.1016\/j.pvr.2017.04.004_bib4","unstructured":"D. Pearce, The Feminization of Poverty: Women, Work, 1978."},{"issue":"2","key":"10.1016\/j.pvr.2017.04.004_bib5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/14649880600768538","article-title":"Re\u2010thinking the \u201cfeminization of poverty\u201d in relation to aggregate gender indices","volume":"7","author":"Chant","year":"2006","journal-title":"J. Hum. Dev."},{"issue":"3","key":"10.1016\/j.pvr.2017.04.004_bib6","first-page":"iii67","article-title":"Feminization of the HIV epidemic in the United States: major research findings and future research needs","volume":"80","author":"Wingood","year":"2003","journal-title":"J. Urban Health"},{"issue":"1\u201311","key":"10.1016\/j.pvr.2017.04.004_bib7","article-title":"What is it to share contraceptive responsibility?","author":"Davis","year":"2015","journal-title":"Topoi"},{"key":"10.1016\/j.pvr.2017.04.004_bib8","series-title":"The Male Pill: a Biography of a Technology in the Making","first-page":"1","article-title":"Designing technology and masculinity: challenging the invisibility of male reproductive bodies in scientific medicine","author":"Oudshoorn","year":"2003"},{"key":"10.1016\/j.pvr.2017.04.004_bib9","article-title":"Running, health and the disciplining of women's bodies: the influence of technology and nature","author":"Little","year":"2016","journal-title":"Health Place"},{"key":"10.1016\/j.pvr.2017.04.004_bib10","article-title":"Power and bodily practice: applying the work of Foucault to an anthropology of the body","author":"Pylypa","year":"1998","journal-title":"Ariz. Anthropol."},{"key":"10.1016\/j.pvr.2017.04.004_bib11","unstructured":"American Cancer Society. History of Cancer Epidemiology. 2014\u00a0[cited 2015 March 4]. Available from: \u3008http:\/\/www.cancer.org\/cancer\/cancerbasics\/thehistoryofcancer\/the-history-of-cancer-cancer-epidemiology\u3009."},{"key":"10.1016\/j.pvr.2017.04.004_bib12","first-page":"507","article-title":"Fatti statistici relativi alle malattie cancerose","volume":"2","author":"Rigoni-Stern","year":"1842","journal-title":"G. per Serv. ai Progress. Della Patol. e Della Ter."},{"issue":"2","key":"10.1016\/j.pvr.2017.04.004_bib13","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1471-0528.1957.tb02620.x","article-title":"Cancer of the uterine cervix: some comments on earlier diagnosis","volume":"64","author":"Lawson","year":"1957","journal-title":"J. Obstet. Gynaecol. Br. Emp."},{"key":"10.1016\/j.pvr.2017.04.004_bib14","first-page":"794","article-title":"Condylomata acuminata and human genital cancer","volume":"36","author":"zur Hausen","year":"1976","journal-title":"Cancer Res."},{"key":"10.1016\/j.pvr.2017.04.004_bib15","first-page":"1","article-title":"Human papilloma viruses and their possible role in squamous cell carcinomas","volume":"78","author":"zur Hausen","year":"1977","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.pvr.2017.04.004_bib16","first-page":"569","article-title":"Human papilloma viruses and cancer","volume":"43","author":"zur Hausen","year":"1975","journal-title":"Bibl. Haematol."},{"issue":"6006","key":"10.1016\/j.pvr.2017.04.004_bib17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/314111a0","article-title":"Structure and transcription of human papillomavirus sequences in cervical carcinoma cells","volume":"314","author":"Schwarz","year":"1985","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.pvr.2017.04.004_bib18","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.virol.2008.11.046","article-title":"Papillomaviruses in the causation of human cancers - a brief historical account","volume":"384","author":"zur Hausen","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.pvr.2017.04.004_bib19","unstructured":"International Agency for Research on Cancer, Human Papillomaviruses. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 64, 1995."},{"issue":"2","key":"10.1016\/j.pvr.2017.04.004_bib20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/ijc.1440","article-title":"Estimating the world cancer burden: Globocan 2000","volume":"94","author":"Parkin","year":"2001","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.pvr.2017.04.004_bib21","doi-asserted-by":"crossref","first-page":"281","DOI":"10.5306\/wjco.v6.i6.281","article-title":"Cervical cancer screening in developing countries at a crossroad: emerging technologies and policy choices","volume":"6","author":"Catarino","year":"2015","journal-title":"World J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.pvr.2017.04.004_bib22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1128\/jvi.67.1.315-322.1993","article-title":"Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins","volume":"67","author":"Hagensee","year":"1993","journal-title":"J. Virol."},{"issue":"24","key":"10.1016\/j.pvr.2017.04.004_bib23","doi-asserted-by":"crossref","first-page":"12180","DOI":"10.1073\/pnas.89.24.12180","article-title":"Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic","volume":"89","author":"Kirnbauer","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"9271","key":"10.1016\/j.pvr.2017.04.004_bib24","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/S0140-6736(00)04956-4","article-title":"Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study","volume":"357","author":"Woodman","year":"2001","journal-title":"Lancet"},{"issue":"9447","key":"10.1016\/j.pvr.2017.04.004_bib25","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"issue":"9706","key":"10.1016\/j.pvr.2017.04.004_bib26","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(09)61567-1","article-title":"Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years","volume":"374","author":"The GlaxoSmithKline Vaccine HPV-007 Study Group.","year":"2009","journal-title":"Lancet"},{"issue":"9686","key":"10.1016\/j.pvr.2017.04.004_bib27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.pvr.2017.04.004_bib28","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet Oncol."},{"issue":"27\u201328","key":"10.1016\/j.pvr.2017.04.004_bib29","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1016\/j.vaccine.2006.04.068","article-title":"Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18","volume":"24","author":"Villa","year":"2006","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.pvr.2017.04.004_bib30","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","article-title":"High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up","volume":"95","author":"Villa","year":"2006","journal-title":"Br. J. Cancer"},{"issue":"RR-05","key":"10.1016\/j.pvr.2017.04.004_bib31","first-page":"1","article-title":"Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Markowitz","year":"2014","journal-title":"MMWR Recomm. Rep."},{"key":"10.1016\/j.pvr.2017.04.004_bib32","unstructured":"Center for Biological Products advisory committee meeting in Food and Drug Administration 2006."},{"issue":"RR-2","key":"10.1016\/j.pvr.2017.04.004_bib33","first-page":"1","article-title":"Quadrivalent human papillomavirus vaccine","volume":"56","author":"Markowitz","year":"2007","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"20","key":"10.1016\/j.pvr.2017.04.004_bib34","first-page":"626","article-title":"FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Centers for Disease Control and Prevention","year":"2010","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"3","key":"10.1016\/j.pvr.2017.04.004_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.2015-1968","article-title":"Prevalence of HPV After Introduction of the Vaccination Program in the United States","volume":"137","author":"Markowitz","year":"2016","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.pvr.2017.04.004_bib36","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/ijc.2910320507","article-title":"Human papillomavirus type-16-related DNA in genital Bowen's disease and in Bowenoid papulosis","volume":"32","author":"Ikenberg","year":"1983","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.pvr.2017.04.004_bib37","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/ijc.2910380509","article-title":"Rearranged HPV 16 molecules in an anal and in a laryngeal carcinoma","volume":"38","author":"Scheurlen","year":"1986","journal-title":"Int. J. Cancer"},{"issue":"9769","key":"10.1016\/j.pvr.2017.04.004_bib38","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S0140-6736(10)62342-2","article-title":"Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study","volume":"377","author":"Giuliano","year":"2011","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.pvr.2017.04.004_bib39","first-page":"630","article-title":"FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Centers for Disease Control and Prevention","year":"2010","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"50","key":"10.1016\/j.pvr.2017.04.004_bib40","first-page":"1705","article-title":"Recommendations on the use of quadrivalent human papillomavirus vaccine in males--Advisory Committee on Immunization Practices (ACIP), 2011","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"12","key":"10.1016\/j.pvr.2017.04.004_bib41","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S1473-3099(10)70219-X","article-title":"Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis","volume":"10","author":"Kim","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.pvr.2017.04.004_bib42","unstructured":"Food and Drug Administration, FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV, 2014. [cited 2015 March 4]. Available from: \u3008http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm426485.htm\u3009."},{"issue":"11","key":"10.1016\/j.pvr.2017.04.004_bib43","first-page":"300","article-title":"Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the Advisory Committee on Immunization Practices","volume":"64","author":"Petrosky","year":"2015","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"8","key":"10.1016\/j.pvr.2017.04.004_bib44","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-Valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pvr.2017.04.004_bib45","unstructured":"Food and Drug Administration, Supplemental Approval, 2015, p. 2."},{"issue":"49","key":"10.1016\/j.pvr.2017.04.004_bib46","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.15585\/mmwr.mm6549a5","article-title":"Use of a 2-dose schedule for human papillomavirus vaccination - updated recommendations of the Advisory Committee on Immunization Practices","volume":"65","author":"Meites","year":"2016","journal-title":"MMWR Morb. Mortal. Wkly.. Rep."},{"key":"10.1016\/j.pvr.2017.04.004_bib47","unstructured":"Food and Drug Administration, Gardasil (R)9, 2006. [cited 2017 March 9]. Available from: \u3008https:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM426457.pdf\u3009."},{"issue":"Suppl 5","key":"10.1016\/j.pvr.2017.04.004_bib48","doi-asserted-by":"crossref","first-page":"F139","DOI":"10.1016\/j.vaccine.2012.05.039","article-title":"Human papillomavirus vaccine introduction--the first five years","volume":"30","author":"Markowitz","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.pvr.2017.04.004_bib49","unstructured":"National Conference of State Legislatures, HPV Vaccine Policies, 2015. [cited 2015 March 4]; Available from: \u3008http:\/\/www.ncsl.org\/research\/health\/hpv-vaccine-state-legislation-and-statutes.aspx\u3009."},{"issue":"5","key":"10.1016\/j.pvr.2017.04.004_bib50","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1177\/0033354916663184","article-title":"Human papillomavirus and mandatory immunization laws: what can we learn from early mandates?","volume":"131","author":"Barraza","year":"2016","journal-title":"Public Health Rep."},{"issue":"8","key":"10.1016\/j.pvr.2017.04.004_bib51","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1056\/NEJMsr1003547","article-title":"HPV vaccination mandates--lawmaking amid political and scientific controversy","volume":"363","author":"Colgrove","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"Suppl 3","key":"10.1016\/j.pvr.2017.04.004_bib52","article-title":"Chapter 6: epidemiology and transmission dynamics of genital HPV infection","volume":"24","author":"Burchell","year":"2006","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.pvr.2017.04.004_bib53","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/OLQ.0000000000000193","article-title":"The estimated lifetime probability of acquiring human papillomavirus in the United States","volume":"41","author":"Chesson","year":"2014","journal-title":"Sex Transm. Dis."},{"key":"10.1016\/j.pvr.2017.04.004_bib54","article-title":"EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus\u2010related cancer incidence by gender and anatomic site of infection","author":"Giuliano","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.pvr.2017.04.004_bib55","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1634\/theoncologist.11-4-393","article-title":"The promise of the human papillomavirus vaccine does not confer immunity against ethical reflection","volume":"11","author":"de Melo-Martin","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.pvr.2017.04.004_bib56","unstructured":"US Preventive Services Task Force. Final Update Summary: Cervical Cancer: Screening. 2016\u00a0[cited 2017 March 9]; Available from: \u3008https:\/\/www.uspreventiveservicestaskforce.org\/Page\/Document\/UpdateSummaryFinal\/cervical-cancer-screening\u3009."},{"issue":"4","key":"10.1016\/j.pvr.2017.04.004_bib57","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1108\/JD-09-2014-0124","article-title":"A feminist information engagement framework for gynecological cancer patients","volume":"71","author":"Westbrook","year":"2015","journal-title":"J. Doc."},{"issue":"5","key":"10.1016\/j.pvr.2017.04.004_bib58","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ypmed.2013.05.013","article-title":"Beliefs, behaviors and HPV vaccine: correcting the myths and the misinformation","volume":"57","author":"Zimet","year":"2013","journal-title":"Prev. Med."},{"key":"10.1016\/j.pvr.2017.04.004_bib59","first-page":"0","article-title":"Tempest in a Teapot: a systematic review of HPV vaccination and risk compensation research","author":"Kasting","year":"2016","journal-title":"Hum. Vaccin Immunother."},{"key":"10.1016\/j.pvr.2017.04.004_bib60","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ypmed.2016.10.007","article-title":"Dispelling the myth: exploring associations between the HPV vaccine and inconsistent condom use among college students","volume":"93","author":"Vazquez-Otero","year":"2016","journal-title":"Prev. Med."},{"issue":"6","key":"10.1016\/j.pvr.2017.04.004_bib61","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/j.1467-9566.2008.01100.x","article-title":"Sex, drugs, and politics: the HPV vaccine for cervical cancer","volume":"30","author":"Casper","year":"2008","journal-title":"Sociol. Health Illn."},{"issue":"12","key":"10.1016\/j.pvr.2017.04.004_bib62","doi-asserted-by":"crossref","first-page":"e115154","DOI":"10.1371\/journal.pone.0115154","article-title":"Vaccinating sons against HPV: results from a U.S. national survey of parents","volume":"9","author":"Taylor","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.pvr.2017.04.004_bib63","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/maq.12046","article-title":"The patient-consumer-advocate nexus: the marketing and dissemination of gardasil, the human papillomavirus vaccine, in the United States","volume":"27","author":"Gottlieb","year":"2013","journal-title":"Med. Anthropol. Q."},{"issue":"4","key":"10.1016\/j.pvr.2017.04.004_bib64","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1080\/08824096.2011.616243","article-title":"Merck's one less campaign: using risk message frames to promote the use of Gardasil\u00ae in HPV prevention","volume":"28","author":"Grantham","year":"2011","journal-title":"Commun. Res. Rep."},{"key":"10.1016\/j.pvr.2017.04.004_bib65","unstructured":"M.A. Redmond, A critical discourse analysis of the marketing of Meck & Co.'s human papillomavirus vaccine Gardasil(R), in College of Arts and Sciences, Georgia State University, 2001."},{"key":"10.1016\/j.pvr.2017.04.004_bib66","unstructured":"M.K. Pisciotta, Gendering Gardasil: Framing Gender and Sexuality in Media Representations of the HPV Vaccine, in Sociology, Portland State University, 2012."},{"key":"10.1016\/j.pvr.2017.04.004_bib67","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1057-6290(08)10003-1","article-title":"Direct to consumer responsibility: medical neoliberalism in pharmaceutical advertising and drug development","volume":"10","author":"Fisher","year":"2001","journal-title":"Adv. Med. Sociol."},{"issue":"7","key":"10.1016\/j.pvr.2017.04.004_bib68","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1136\/jech.2008.074740","article-title":"Human papillomavirus (HPV) vaccination and the development of public policies","volume":"62","author":"Lippman","year":"2008","journal-title":"J. Epidemiol. Community Health"},{"issue":"4","key":"10.1016\/j.pvr.2017.04.004_bib69","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1080\/00224499.2011.644598","article-title":"From desire to disease: human papillomavirus (HPV) and the medicalization of nascent female sexuality","volume":"49","author":"Polzer","year":"2012","journal-title":"J. Sex Res."},{"issue":"29","key":"10.1016\/j.pvr.2017.04.004_bib70","doi-asserted-by":"crossref","first-page":"784","DOI":"10.15585\/mmwr.mm6429a3","article-title":"National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years--United States, 2014","volume":"64","author":"Reagan-Steiner","year":"2015","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"5","key":"10.1016\/j.pvr.2017.04.004_bib71","doi-asserted-by":"crossref","first-page":"946","DOI":"10.2105\/AJPH.2013.301828","article-title":"Vaccination interest and trends in human papillomavirus vaccine uptake in young adult women aged 18 to 26 years in the United States: an analysis using the 2008\u20132012 National Health Interview Survey","volume":"104","author":"Schmidt","year":"2014","journal-title":"Am. J. Public Health"},{"issue":"49","key":"10.1016\/j.pvr.2017.04.004_bib72","doi-asserted-by":"crossref","first-page":"6655","DOI":"10.1016\/j.vaccine.2014.09.044","article-title":"Human papillomavirus vaccine uptake among males 11-26 years in United States: findings from the National Health and Nutrition Examination Survey, 2011\u20132012","volume":"32","author":"Pierre-Victor","year":"2014","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.pvr.2017.04.004_bib73","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/infdis\/jit192","article-title":"Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003\u20132010","volume":"208","author":"Markowitz","year":"2013","journal-title":"J. Infect. Dis."},{"issue":"46","key":"10.1016\/j.pvr.2017.04.004_bib74","doi-asserted-by":"crossref","first-page":"8443","DOI":"10.1016\/j.vaccine.2011.07.096","article-title":"The cost-effectiveness of male HPV vaccination in the United States","volume":"29","author":"Chesson","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.pvr.2017.04.004_bib75","unstructured":"Anonymous, Details omitted for double-blind reviewing, 2016."},{"issue":"17","key":"10.1016\/j.pvr.2017.04.004_bib76","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"Palefsky","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.pvr.2017.04.004_bib77","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/aje\/kwg067","article-title":"Cancer in a Population-based Cohort of Men and Women in Registered Homosexual Partnerships","volume":"157","author":"Frisch","year":"2003","journal-title":"Am. J. Epidemiol."},{"issue":"5","key":"10.1016\/j.pvr.2017.04.004_bib78","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(14)71073-4","article-title":"Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis","volume":"15","author":"Drolet","year":"2015","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/j.pvr.2017.04.004_bib79","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/OLQ.0b013e3181ebd50f","article-title":"Physician awareness of sexual orientation and preventive health recommendations to men who have sex with men","volume":"38","author":"Petroll","year":"2011","journal-title":"Sex. Transm. Dis."},{"issue":"32","key":"10.1016\/j.pvr.2017.04.004_bib80","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1200\/JCO.2011.36.4596","article-title":"Human papillomavirus and rising oropharyngeal cancer incidence in the United States","volume":"29","author":"Chaturvedi","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.pvr.2017.04.004_bib81","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/jnci\/djs491","article-title":"Annual report to the nation on the status of cancer, 1975\u20132009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels","volume":"105","author":"Jemal","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.pvr.2017.04.004_bib82","unstructured":"H.W. Chesson, Overview of cost-effectiveness of 9-valent HPV vaccination, in Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention: Atlanta, GA, 2015."},{"key":"10.1016\/j.pvr.2017.04.004_bib83","unstructured":"M. Brisson, Cost effectiveness of 9-valent HPV vaccination, in Advisory Committee on Immunization Practices, Summary Report, October 29-30 2014, Centers for Disease Control and Prevention: Atlanta, GA, 2014."},{"issue":"Suppl 1","key":"10.1016\/j.pvr.2017.04.004_bib84","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.ypmed.2011.08.001","article-title":"The role of HPV in head and neck cancer and review of the HPV vaccine","volume":"53","author":"D\u2019Souza","year":"2011","journal-title":"Prev. Med."},{"issue":"2","key":"10.1016\/j.pvr.2017.04.004_bib85","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s10900-013-9773-y","article-title":"Ethnic and gender differences in HPV knowledge, awareness, and vaccine acceptability among white and hispanic men and women","volume":"39","author":"Reimer","year":"2014","journal-title":"J. Community Health"},{"issue":"3","key":"10.1016\/j.pvr.2017.04.004_bib86","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/sextrans-2013-051402","article-title":"Knowledge of human papillomavirus (HPV) testing in the USA, the UK and Australia: an international survey","volume":"90","author":"Dodd","year":"2014","journal-title":"Sex Transm. Infect."},{"key":"10.1016\/j.pvr.2017.04.004_bib87","first-page":"0","article-title":"Comparing human papillomavirus vaccine knowledge and intentions among parents of boys and girls","author":"Lindley","year":"2016","journal-title":"Hum. Vaccin Immunother."},{"issue":"41","key":"10.1016\/j.pvr.2017.04.004_bib88","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1016\/j.vaccine.2012.07.045","article-title":"Do correlates of HPV vaccine initiation differ between adolescent boys and girls?","volume":"30","author":"Gilkey","year":"2012","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.pvr.2017.04.004_bib89","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.pedhc.2014.05.003","article-title":"HPV vaccine hesitancy: findings from a statewide survey of health care providers","volume":"28","author":"McRee","year":"2014","journal-title":"J. Pediatr. Health Care"},{"issue":"8","key":"10.1016\/j.pvr.2017.04.004_bib90","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.2105\/AJPH.2012.301189","article-title":"Longitudinal predictors of human papillomavirus vaccination among a national sample of adolescent males","volume":"103","author":"Reiter","year":"2013","journal-title":"Am. J. Public Health"},{"issue":"6","key":"10.1016\/j.pvr.2017.04.004_bib91","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1177\/1059840511415861","article-title":"The uptake of human papillomavirus (HPV) vaccine among adolescent females in the United States: a review of the literature","volume":"27","author":"Bartlett","year":"2011","journal-title":"J. Sch. Nurs."},{"issue":"5","key":"10.1016\/j.pvr.2017.04.004_bib92","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.vaccine.2009.12.063","article-title":"Predictors of HPV vaccine uptake among women aged 19-26: importance of a physician's recommendation","volume":"29","author":"Rosenthal","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.pvr.2017.04.004_bib93","unstructured":"National Center for Health Statistics. Health, United States, 2015 - Men's Health, 2016.\u00a0[cited 2017 March 9]. Available from: \u3008https:\/\/www.cdc.gov\/nchs\/hus\/men.htm#preventive\u3009."},{"key":"10.1016\/j.pvr.2017.04.004_bib94","unstructured":"Healthy People 2020. Immunization and Infectious Diseases, 2015.\u00a0[cited 2016 April 6]. Available from: \u3008http:\/\/www.healthypeople.gov\/2020\/topics-objectives\/topic\/immunization-and-infectious-diseases\/objectives\u3009."},{"key":"10.1016\/j.pvr.2017.04.004_bib95","doi-asserted-by":"crossref","DOI":"10.1503\/cmaj.150451","article-title":"A policy analysis of the decision to include males in Canadia HPV vaccination programs","author":"Shaprio","year":"2016","journal-title":"Can. Med. Assoc. J."},{"key":"10.1016\/j.pvr.2017.04.004_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2016.03.022","article-title":"Rates of human papillomavirus vaccine uptake amongst girls five years after introduction of statewide mandate in Virginia","author":"Cuff","year":"2016","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.pvr.2017.04.004_bib97","doi-asserted-by":"crossref","DOI":"10.1158\/1055-9965.EPI-15-0326","article-title":"Quality of physician communication about human papillomavirus vaccine: findings from a national survey","author":"Gilkey","year":"2015","journal-title":"Cancer Epidemiol. Biomark. Prev."}],"container-title":["Papillomavirus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405852116300593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405852116300593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T11:03:13Z","timestamp":1762513393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405852116300593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":97,"alternative-id":["S2405852116300593"],"URL":"https:\/\/doi.org\/10.1016\/j.pvr.2017.04.004","relation":{},"ISSN":["2405-8521"],"issn-type":[{"value":"2405-8521","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The feminization of HPV: How science, politics, economics and gender norms shaped U.S. HPV vaccine implementation","name":"articletitle","label":"Article Title"},{"value":"Papillomavirus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pvr.2017.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}